Additionally, inhibiting TIGIT enhances tumor-specific T cell immunity through an NK cell-dependent process, improves therapeutic results with anti-PD-L1 antibodies, and extends memory immunity during tumor rechallenge in animals (Zhang et al., 2018) (Figure 2). The gene discussed is CD274; the disease is neoplasm.